First human test of new 'Living Drug' for Tough-to-Treat cancers

This is a first-in-human study to check the safety of a new, personalized cell therapy called M-CENK, given with a drug named N-803, for adults with advanced solid tumors that have spread or stopped responding to other treatments. The therapy involves collecting a patient's own immune cells, growing them in a lab to boost their cancer-fighting ability, and then infusing them back. The main goal is to see if this approach is safe and to get an early look at whether it might help control the cancer.